Department of Ophthalmology, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul, 03080, South Korea; Laboratory of Ocular Regenerative Medicine and Immunology, Biomedical Research Institute, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 03080, South Korea.
Department of Ophthalmology, Hallym University Sacred Heart Hospital, 22, Gwanpyeong-ro 170 Beon-gil, Dongan-gu, Anyang-si, Gyeonggi-do, 14068, South Korea.
Ocul Surf. 2021 Jan;19:16-30. doi: 10.1016/j.jtos.2020.11.006. Epub 2020 Nov 22.
Local chemotherapy is increasingly used, either in combination with surgery or as monotherapy, for management of ocular tumors. Yet many of the local chemotherapeutic agents used for ocular tumors are cytotoxic drugs that are frequently associated with toxicities in normal ocular tissues. Understanding and managing these side effects are important because they affect treatment tolerability, outcome and quality of vision. Herein, we review local anticancer drugs administered for the treatment of ocular tumors, with an emphasis on their toxicities to the ocular surface, adnexa and lacrimal drainage system. We provide the underlying mechanisms and management strategies for the ocular side effects. Recent innovations in anticancer immunotherapy and ocular drug delivery systems also are discussed as new potential therapeutic modalities for alleviation of side effects.
局部化疗越来越多地被用于眼部肿瘤的治疗，无论是联合手术还是单独使用。然而，许多用于眼部肿瘤的局部化疗药物是细胞毒性药物，这些药物经常与正常眼部组织的毒性有关。了解和管理这些副作用非常重要，因为它们会影响治疗的耐受性、结果和视力质量。在此，我们综述了用于治疗眼部肿瘤的局部抗癌药物，重点讨论了它们对眼表面、附属器和泪液引流系统的毒性。我们提供了眼部副作用的潜在机制和管理策略。还讨论了最近的抗癌免疫治疗和眼部药物传递系统的创新，作为减轻副作用的新的潜在治疗方法。
